Equities research analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report $7.92 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest sales estimate is $5.55 million and the highest is $11.00 million. Stemline Therapeutics posted sales of $500,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 1,484%. The firm is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that Stemline Therapeutics will report full-year sales of $38.97 million for the current fiscal year, with estimates ranging from $23.80 million to $54.38 million. For the next fiscal year, analysts forecast that the company will report sales of $134.20 million, with estimates ranging from $87.36 million to $207.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million.

Several equities analysts have recently issued reports on the stock. Roth Capital reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, May 23rd. ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. BidaskClub downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Wedbush cut shares of Stemline Therapeutics from an “outperform” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research report on Monday, May 13th. They noted that the move was a valuation call. Finally, Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 18th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and a consensus target price of $25.20.

Shares of STML stock traded down $0.13 during trading hours on Friday, hitting $13.29. 296,805 shares of the company’s stock traded hands, compared to its average volume of 631,847. The company has a market capitalization of $586.25 million, a P/E ratio of -4.44 and a beta of 1.25. Stemline Therapeutics has a 12 month low of $7.82 and a 12 month high of $18.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.07.

In other news, COO Kenneth Hoberman sold 25,817 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total transaction of $368,408.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 14.80% of the company’s stock.

Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Stemline Therapeutics during the 1st quarter valued at about $36,000. Great West Life Assurance Co. Can bought a new position in Stemline Therapeutics in the fourth quarter worth $47,000. Legal & General Group Plc lifted its position in Stemline Therapeutics by 27.1% in the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,120 shares during the period. BNP Paribas Arbitrage SA bought a new position in Stemline Therapeutics in the first quarter worth $102,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Stemline Therapeutics by 327.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 6,527 shares during the period. Institutional investors and hedge funds own 77.66% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.